指南与共识胸部肿瘤

推进肺癌分期:整合IASLC推荐与生物信息学判定肿瘤起源

Advancing Lung Cancer Staging: Integrating IASLC Recommendations and Bioinformatics to Delineate Tumor Origins.
指南 / 共识 · J Thorac Oncol · 2025-10-22

该研究评估IASLC算法分子组分对多灶性非小细胞肺癌克隆性判定的价值,分析120例患者240对肿瘤样本的小规模基因面板NGS结果。小规模测序可使四分之三病例明确克隆性,大规模测序解决约半数不确定病例,新生物信息学方法将不确定对降至2%,克隆性分类与总生存显著相关。

要点

  • 小规模基因面板测序可在四分之三病例中明确克隆性。
  • 大规模测序可解决约半数分子分类不确定的病例。
  • 新生物信息学方法将不确定对降至2%,已公开为Shiny App。

核心结论

  • 小规模面板测序可对四分之三病例明确克隆性,大规模测序解决约半数不确定病例,新生物信息学方法将不确定对降至2%。
  • 克隆性分类与总生存相关,SPLCs总生存显著长于IPMs。

研究设计与样本

  • 研究聚焦IASLC算法分子组分,评估120例患者240对FFPE肿瘤样本的小规模基因面板NGS(31-54基因)结果。
  • 多数肿瘤为腺癌(n=222),其余18个为其他NSCLC亚型;分子分类不确定对接受大规模面板分析(531基因)。
  • 开发补充和优化IASLC方法的生物信息学方法。

主要发现

  • 分子IASLC方法下22对肿瘤(18%)仍不确定,16对(13%)分类为模糊(可能SPLCs)。
  • 重新测序将22对不确定中的9对分类为IPMs。
  • 新生物信息学方法仅3对(2%)仍不确定。
  • 分类为SPLCs的肿瘤总生存显著长于IPMs。

临床怎么用

  • 小规模面板测序活检材料可明确多数病例克隆性,减少不确定结果。
  • 新生物信息学方法可公开获取为Shiny App,辅助日常临床克隆性判定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Accurate distinction between separate primary lung carcinomas (SPLCs) and intrapulmonary metastases (IPMs) is essential for staging and treatment of multifocal NSCLC. Next-generation sequencing (NGS) enables assessment of clonal relatedness. The proposed International Association for the Study of Lung Cancer (IASLC) algorithm integrates histologic and molecular data, though its clinical utility is yet to be validated. METHODS: We focused on the molecular component of the algorithm and assessed 240 tumor pairs from 120 patients with formalin-fixed, paraffin-embedded tumor samples that underwent small-scale gene-panel NGS testing (31-54 genes) within routine clinical care. Most tumors were adenocarcinomas (n = 222), with 18 tumors other NSCLC subtypes. Inconclusive pairs by molecular classification were subjected to large-scale panel analyses (531 genes). In addition, we developed a bioinformatic method to complement and refine the IASLC method. RESULTS: In total, 22 tumor pairs (18%) remained inconclusive and 16 (13%) were classified ambiguous (probable SPLCs) using the molecular IASLC method. Resequencing classified nine of 22 inconclusive pairs as IPMs. Using a newly developed bioinformatic method for clonality classification incorporating likelihood ratios of mutational prevalence and small-scale sequencing, only three pairs remained inconclusive (2%). Tumors classified as SPLCs had a significantly longer overall survival than IPMs. CONCLUSIONS: Small-scale panel sequencing of biopsy material allows unambiguous clonality determination in three of four cases. Large-scale sequencing resolves approximately half of inconclusive cases. Our bioinformatic method reduces inconclusive pairs to 2% even with small-scale NGS. It is made publicly available as a Shiny App. Clonality is reflected in survival data and therefore pivotal in daily clinical practice.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Allgäuer M, Kluck K, Christopoulos P, et al. Advancing Lung Cancer Staging: Integrating IASLC Recommendations and Bioinformatics to Delineate Tumor Origins. J Thorac Oncol. 2025. PMID: 41135642. doi:10.1016/j.jtho.2025.10.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。